Table 3 Clinicopathologic characteristics of DDLPS (whole section) and UPS (TMA)
From: Status of programmed death-ligand 1 expression in sarcomas
DDLPS, whole section | UPS, TMA | |||||||
|---|---|---|---|---|---|---|---|---|
Total | Negative | Positive | P | Total | Negative | Positive | P | |
N | 32 | 25 | 7 | 60 | 48 | 12 | ||
Age, year (median) | 56 | 55 | 58 | 0.616 | 53 | 55 | 42.5 | 0.132 |
M:F | 19:13 | 15:10 | 4:3 | > 0.99 | 32:28 | 28:20 | 4:8 | 0.121 |
Chemotherapy, n (%) | 6/32 (18.8%) | 5/25 (20.0%) | 1/7 (14.3%) | > 0.99 | 27/60 (45.0%) | 21/48 (43.8%) | 6/12 (50%) | 0.754 |
Radiation therapy, n (%) | 20/32 (62.5%) | 15/25 (60.0%) | 5/7 (71.4%) | 0.683 | 30/60 (50%) | 22/48 (45.8%) | 8/12 (66.7%) | 0.197 |
Recurrence, n (%) | 11/32 (34.4%) | 8/25 (32.0%) | 3/7 (42.9%) | 27/60 (45.0%) | 22/48 (45.8%) | 5/12 (41.7%) | ||
Expire, n (%) | 3/32 (9.4%) | 1/25 (4.0%) | 2/7 (28.6%) | 36/60 (60.0%) | 29/48 (60.4%) | 7/12 (58.3%) | ||
Tumor size (cm, median) | 12.75 | 12.5 | 14 | 0.569 | 6 | 5.35 | 7 | 0.523 |
Resection margin involved, n (%) | 28/32 (87.5%) | 22/25 (88.0%) | 6/7 (85.7%) | > 0.99 | 25/49 (51.0%) | 21/39 (53.8%) | 4/10 (40.0%) | 0.496 |
FNCLCC | ||||||||
2 | 28/32 (87.5%) | 23/25 (92.0%) | 5/7 (71.4%) | 0.201 | 17/41 (41.5%) | 14/33 (42.4%) | 3/8 (37.5%) | > 0.99 |
3 | 4/32 (12.5%) | 2/25 (8.0%) | 2/7 (28.6%) | 24/41 (58.5%) | 19/33 (57.6%) | 5/8 (62.5%) | ||